For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenue | - | - | - | 62,750 |
| Research and development (including related party amounts of 13, 1,342, 63 and 2,802, respectively) | 17,633,000 | 17,861,000 | 17,052,000 | 12,235,500 |
| General and administrative | 5,264,000 | 4,949,000 | 5,119,000 | 4,268,500 |
| Total operating expenses | 22,897,000 | 22,810,000 | 22,171,000 | 16,504,000 |
| Loss from operations | -22,897,000 | -22,810,000 | -22,171,000 | -16,378,500 |
| Change in fair value of safes (including related party amounts of 2,911 and 573, respectively) | - | - | - | -134,000 |
| Interest income | 1,372,000 | 1,561,000 | 1,864,000 | 99,250 |
| Other (expense) income, net | -3,000 | -5,000 | -4,000 | 70,000 |
| Total other income (expense), net | 1,369,000 | 1,556,000 | 1,860,000 | 35,250 |
| Loss before provision for income taxes | - | - | - | -16,343,250 |
| Provision for income taxes | - | - | - | 1,314,250 |
| Net loss | -21,528,000 | -21,254,000 | -20,311,000 | -15,029,000 |
| Unrealized gain (loss) on investments, net | - | 2,000 | 129,000 | -284,000 |
| Unrealized gain on investments, net | 85,000 | - | - | - |
| Comprehensive loss | -21,443,000 | -21,252,000 | -20,182,000 | -15,313,000 |
| Earnings per share, basic | -0.88 | -0.87 | -0.83 | 8.555 |
| Earnings per share, diluted | -0.88 | -0.87 | -0.83 | 8.555 |
| Weighted average number of shares outstanding, basic | 24,481,722 | 24,378,823 | 24,341,978 | -4,224,594 |
| Weighted average number of shares outstanding, diluted | 24,481,722 | 24,378,823 | 24,341,978 | -4,224,594 |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)